rexahn
pharmaceuticals
announces
expected
effectiveness
reverse
stock
split
merger
transaction
ocuphire
pharma
rockville
globe
newswire
rexahn
pharmaceuticals
nasdaq
rexn
rexahn
announced
today
merger
transaction
rexahn
ocuphire
pharma
expected
effective
shortly
pm
est
today
thursday
november
previously
announced
rexahn
stockholders
voted
approve
proposals
required
complete
merger
transaction
connection
approvals
board
directors
rexahn
approved
reverse
stock
split
rexahn
common
stock
ratio
one
share
every
shares
outstanding
expected
become
effective
immediately
prior
effectiveness
merger
immediately
following
effectiveness
merger
combined
company
renamed
ocuphire
pharma
expected
begin
trading
nasdaq
capital
market
stock
split
basis
new
ticker
symbol
ocup
friday
november
new
cusip
number
statements
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
statements
include
limited
statements
concerning
effectiveness
reverse
stock
split
merger
ocuphire
well
combined
company
expected
listing
nasdaq
capital
market
parties
may
actually
effect
foregoing
transactions
otherwise
carry
intentions
meet
expectations
projections
disclosed
statements
place
undue
reliance
statements
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
statements
based
upon
rexahn
ocuphire
current
expectations
involve
assumptions
may
never
materialize
may
prove
incorrect
actual
results
timing
events
could
differ
materially
anticipated
statements
result
various
risks
uncertainties
include
without
limitation
risks
associated
timing
effectiveness
reverse
stock
split
merger
transaction
including
risks
reverse
stock
split
proposed
merger
occur
ii
outcome
legal
proceedings
may
instituted
parties
others
related
merger
agreement
iii
whether
nasdaq
capital
market
continue
list
common
shares
combined
company
following
merger
iv
occurrence
event
change
circumstance
condition
could
give
rise
termination
merger
agreement
v
unanticipated
difficulties
expenditures
relating
proposed
merger
transaction
response
business
partners
competitors
announcement
effectiveness
merger
transaction
vi
whether
combined
business
rexahn
ocuphire
successful
vii
risks
detailed
rexahn
recent
annual
report
form
fiscal
year
ended
december
subsequent
reports
filed
sec
well
documents
may
filed
rexahn
time
time
sec
including
proxy
statement
prospectus
included
certain
registration
statement
form
file
initially
filed
sec
july
declared
effective
sec
october
statements
contained
press
release
speak
date
made
rexahn
undertakes
obligation
update
statements
reflect
events
occur
circumstances
exist
date
made
rexahn
contact
douglas
swirsky
president
ceo
rexahn
pharmaceuticals
swirskyd
ocuphire
contact
mina
sooch
president
ceo
ocuphire
pharma
msooch
